Recent advancements in immunotherapy, notably the application of pembrolizumab—an anti-PD-1 antibody—have demonstrated remarkable efficacy in treating various cancer types, including microsatellite instability-high (MSI-H)/mismatch repair deficient (MMRd) metastatic colorectal cancer (CRC) and programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC), significantly prolonging progression-free and overall survival1,2. This evidence concerns the gene CD274 and colorectal carcinoma.